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http://www.biomedcentral.com/1471-2407/14/332RESEARCH ARTICLE Open AccessDiffuse large B cell lymphoma derived from
nodular lymphocyte predominant Hodgkin
lymphoma presents with variable histopathology
Sylvia Hartmann1*, Mine Eray2, Claudia Döring1, Tuula Lehtinen3, Uta Brunnberg4, Paula Kujala2,
Martine Vornanen2† and Martin-Leo Hansmann1†Abstract
Background: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) usually presents in middle aged men
and shows an indolent clinical behavior. However, up to 30% of the patients present a secondary transformation
into aggressive diffuse large B cell lymphoma (DLBCL). The aim of the present study was to characterize
morphology and immunophenotype of this kind of DLBCL in detail and compare it with conventional DLBCL.
Methods: Morphology and immunophenotype of 33 cases of NLPHL with simultaneous or sequential
transformation into DLBCL were investigated. These cases were compared with 41 de novo DLBCL in Finnish men.
Results: The majority of cases exhibited different immunophenotypes in the NLPHL and the DLBCL components.
The immunophenotype of the DLBCL secondary to NLPHL was heterogeneous. However, BCL6, EMA, CD75 and
J-chain were usually expressed in both components (≥73% positive). Overall, the NLPHL component was more
frequently positive for EMA, CD75 and J-chain than the DLBCL component. In contrast, B cell markers, CD10 and
BCL2, were more frequently expressed and were expressed at higher levels in the DLBCL component than in the
NLPHL component. In the independent series of de novo DLBCL 4 cases could be identified with a growth pattern
and immunophenotype that suggested that they had arisen secondarily from NLPHL.
Conclusions: The morphology and immunophenotype of DLBCL arisen from NLPHL is heterogeneous. Further
characterization of the particular molecular features of this subgroup is warranted to be able to better identify these
cases among conventional DLBCL.
Keywords: Nodular lymphocyte predominant Hodgkin lymphoma, Diffuse large B cell lymphoma, TransformationBackground
Nodular lymphocyte predominant Hodgkin lymphoma
(NLPHL) is a rare subtype of Hodgkin lymphoma (HL),
which accounts for approximately 5% of all cases [1] and
generally presents with early clinical stages and an indolent
clinical behavior [2,3]. Middle aged males account for
75% of cases [3]. Histologically, NLPHL typically consists
of large nodules of reactive small B cells with a few
intermingled tumor cells, the so called lymphocyte
predominant or LP cells. Morphologic variants with a* Correspondence: s.hartmann@em.uni-frankfurt.de
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reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.diffuse pattern or an abundant reactive T cell infiltrate
mimicking T cell/histiocyte rich B cell lymphoma
(THRLBCL) have been described [4,5]. Gene expression
profiling studies have identified only marginal differences
between LP cells and tumor cells of THRLBCL [6,7]. In
contrast to Hodgkin and Reed-Sternberg cells of classical
HL, LP cells usually show a preserved or only partially
downregulated B cell phenotype [6,8]. They typically
exhibit constitutive NF-kappaB activity [6] and active
JAK-STAT-signaling [9]. Recently, germline mutations of
the NPAT gene have been identified as risk factor for
NLPHL in the Finnish population [10] and there are
reports about a high familial risk in first degree relatives of
NLPHL patients [11,12].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinical characteristics of patients studied
NLPHL-DLBCL
(n = 33)
Conventional
DLBCL (n = 41)
Patients with simultaneous
involvement by NLPHL and DLBCL
26 -
Patients with sequential
involvement by NLPHL and DLBCL
7 -
Median patient age (range) 50 (19–78) 69 (19–93)
male gender (%) 85 100*
Biopsy site
- axillary 12 (36%) 4 (10%)
- cervical/supraclavicular 9 (27%) 26 (63%)
- abdominal/mesenteric LN/bowel 8 (24%) 5 (12%)
- inguinal 4 (12%) 1 (2%)
- mediastinal/retroperitoneal 0 3 (7%)
- other 0 2 (5%)
Splenic involvement 30% 5%
Stage**
- I 2 (9%) 7 (17%)
- II 4 (18%) 12 (29%)
- III 6 (27%) 12 (29%)
- IV 10 (45%) 10 (24%)
*only male patients were selected.
**Clinical stages were available in 22 of 33 NLPHL-DLBCL composite lymphomas.
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transformation of NLPHL into diffuse large B cell
lymphoma (DLBCL) has been described in up to 30% of
cases [13-18]. Several studies have suggested that these
patients have a favorable outcome [13,14,16,17,19].
However, one study did not confirm this observation [15].
The male: female ratio for cases of NLPHL transformed
into DLBCL was slightly higher than for primary NLPHL
(77 - 81%) [14-17]. The aim of the present study was to
characterize morphology and immunophenotype of
DLBCL simultaneously or sequentially derived from
NLPHL in 33 cases. A second aim was the comparison of
the immunophenotype observed in these particular cases
with conventional DLBCL, in order to identify a marker
panel, which allows to detect DLBCL, representing a
putative transformation from NLPHL, in an independent
series of DLBCL.
Methods
Tissue samples
A series of 33 consecutive cases of composite lymphoma
of NLPHL and DLBCL were identified from the archives
of the Dr. Senckenberg Institute of Pathology, Goethe
University, Frankfurt am Main, Germany and the
Department of Pathology, Tampere University Hospital,
Tampere, Finland. Original diagnoses were made between
1987 and 2013. Original slides were complemented by
additional stainings (see below). All diagnoses could be
confirmed according to the WHO classification 2008 after
joint review (S.H., M.E., M.V. and in part M.L.H.). In 26
cases both the NLPHL and DLBCL were present in
the same biopsy, and in 7 cases, the DLBCL occurred
sequentially after NLPHL. Two patients with simultaneous
presentation of NLPHL and DLBCL had a previous
history of NLPHL. NLPHL cases with transformation
into pure THRLBCL were not included in the present
study, since different mechanisms of transformation
may be involved in these cases.
In a second step, 41 consecutive cases of male patients
with DLBCL, diagnosed at the Pathology Department
of Tampere University between 2003 and 2010, were
selected from the archives and analyzed to identify
cases representing a transformation from NLPHL
(“LP-type DLBCL”).
The study was approved by the local ethics committees
of Frankfurt and Tampere University Hospital (ethics
votes 120/13 from May, 23rd 2013 and 7085/05.01.00.06/
2010 from October, 5th 2010).
Immunohistochemistry
All composite cases of NLPHL and DLBCL were investi-
gated for CD20, CD79a, CD19, CD3, EMA, J-chain, CD75,
CD10, BCL2, BCL6, CD30, CD15, MUM1, IgD, p-STAT6,
JAK2 and EBER.The cases of the second series of DLBCL were stained
for CD20, CD3, CD10, BCL6, BCL2, CD75, EMA, J-chain
and MUM1. In cases where transformation from NLPHL
seemed likely, the specimens were additionally studied for
IgD, CD30, CD15, and EBER. Twenty-eight cases each of
DLBCL derived from NLPHL and conventional DLBCL
were evaluated for the presence of follicular dendritic cells
(FDCs) by CD21 and CD23.
Immunostainings were performed in the Pathology
departments of Frankfurt and Tampere University
using either an Alkaline Phosphatase-Real Detection Kit
(DAKO, Glostrup, Denmark) or Peroxidase-EnVision Plus
Kit (DAKO) as described previously [20]. The antibodies
used, dilutions, and providers are listed in Additional file 1:
Table S1. Antigen unmasking was performed for 3 min in
a pressure cooker in TRIS-EDTA pH 8.0. All stainings
were assessed using a multi-head microscope, and were
scored as positive or weakly positive if > 50% of the tumor
cells showed a reaction with the respective antibodies.
Positivity perceivable at low magnification (4×) was scored
strongly positive, positivity only noticeable at higher
magnification was scored weakly positive. Intensity of B
cell markers (CD20, CD79a, CD19) was scored weakly
positive if the expression intensity was weaker than in
small reactive B cells. In the composite cases it was also
assessed, if the tumor cells in the DLBCL component
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with the LP cells in the NLPHL component.
Results
Clinical and morphologic findings of NLPHL + DLBCL
composite lymphomas
Twenty-six patients presented with NLPHL and DLBCL
simultaneously in the same lymph node. Seven patients
developed sequential DLBCL secondary to the previous
diagnosis of NLPHL with a median time to trans-
formation of 8 years. The median patient age (50 years)
did not differ between patients with simultaneous or
sequential presentation of the disease. Detailed clinical
characteristics are displayed in Table 1. In twenty
patients, the treatment and follow up was known: 65% of
the patients were treated by R-CHOP, 10% received
ABVD, 10% did not receive any treatment due to poor
performance status. One patient received rituximab only,
and two patients underwent autologous stem cell
transplantation. The median follow up time in these
20 patients was 21 months (21.5 months for alive patients),
and the estimated 8-year progression free survival
(PFS) and overall survival (OS) rates were 69% and
54%, respectively. Patients with sequential transformation
showed a non-significant trend towards worse overallFigure 1 Typical infiltration patterns of “LP type” DLBCL in composite
HE (40×). b. Sharply demarcated blast infiltrate, CD20 (40×). c. Sharply dem
(CD20, 40×). d. DLBCL with abundant necrosis and blast infiltrate predominand progression free survival compared to patients
with simultaneous presentation of NLPHL and DLBCL
(Additional file 2: Figure S1).
Morphologic findings of NLPHL + DLBCL composite
lymphomas
The ratios of the NLPHL and DLBCL components were
heterogeneous in the infiltrated tissue. In some cases,
only a few nodules of NLPHL could be observed at the
margins of the tissue effaced by the DLBCL. The
NLPHL component showed a typical nodular pattern in
10 cases (pattern A according to Fan et al. [4]);
whereas, 23 cases presented T cell rich and diffuse
patterns (patterns non-A/B). DLBCL transformed from
NLPHL consisted either of nodular, sharply demarcated,
large cohesive sheets of blasts with few bystander
cells (21 cases, Figure 1a and b) or of small sheets of
blasts, with an abundant T cell and histiocyte infiltrate
(12 cases, Figure 1c and d). These latter cases were
reminiscent of T cell/histiocyte rich large B cell
lymphoma, but the tumor cell content was greater
than 10% of the total infiltrate and the blasts formed
small clusters. Whereas necrosis was never observed
in NLPHL, four cases showed necrotic foci within the
DLBCL component. In these areas, the blasts showedlymphomas. a. Sharply demarcated infiltrate of pale staining blasts,
arcated blast infiltrate with T cell and histiocyte rich microenvironment
antly in perivascular localization (CD20, 40×).
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In all cases the blasts exhibited large nuclei compared with
common de novo DLBCL, and presented a broad, pale
cytoplasm. The morphologies of the nuclei were variable
(12 centroblastic polymorph, 11 multilobated, 6 anaplastic,
3 centroblastic monomorph, 1 immunoblastic).
Immunophenotype of NLPHL + DLBCL composite
lymphomas
Immunostainings were scored positive, weakly positive, or
negative in the tumor cells of both NLPHL and DLBCL
components. The intensity of the staining of both compo-
nents was compared and was also recorded if enhanced
or reduced expression in the DLBCL component was
observed (Table 2).
The immunophenotype of neoplastic cells in both the
NLPHL part and the DLBCL components were largely
consistent with the immunophenotype previously reported
for LP cells [1]. However, 32 of 33 cases showed a difference
in the immunophenotype or intensity between NLPHL and
DLBCL in at least one staining. BCL6 and CD79a were
expressed in the tumor cells of both components in all
cases. CD75, EMA, and J-chain were expressed in most
cases in the LP cells of NLPHL (97%, 82%, and 82% of the
cases, respectively, Table 2, Figure 2) and in the tumor cells
of the DLBCL component (94%, 73%, and 73% of the cases,
respectively). Although attenuation or loss of expression of
EMA and J-chain was observed in the DLBCL com-
ponent, these markers were significantly more frequently
positive compared with conventional DLBCL (p < 0.05,Table 2 Immunophenotype of composite lymphomas with NL
Immuno-staining DLBCL
component
positive
LP cells
positive
Reduced expression
in DLBCL component e
Bcl6 33/33 (100%) 33/33 (100%) 3%
CD79a 33/33 (100%) 33/33 (100%) 0%
CD19 32/33 (97%) 25/32 (78%) 3%
CD75 31/33 (94%) 32/33 (97%) 12%
EMA 24/33 (73%) 27/33 (82%) 18%
J-chain 24/33 (73%) 27/33 (82%) 27%
Bcl2* 20/32 (63%) 27/33 (82%) 0%
MUM1 21/33 (63%) 24/32 (72%) 13%
JAK2 12/30 (40%) 4/27 (15%) 0%
CD10 12/33 (36%) 2/33 (6%) 0%
p-STAT6 9/30 (30%) 8/26 (31%) 9%
CD30 7/33 (21%) 7/33 (21%) 6%
CD15 4/33 (12%) 2/33 (6%) 0%
IgD 4/33 (12%) 5/33 (15%) 3%
Immunohistochemical stainings were assessed separately in the NLPHL and DLBCL
decreased staining intensity in the DLBCL component compared to the LP cells in N
*Since BCL2 was usually negative or weakly positive in LP cells, the frequency of ne2-Tail Fisher´s Exact Test, see below). MUM1 was weakly
expressed as is typically observed in germinal center B
cells [21] at approximately the same frequency in both
the NLPHL and DLBCL components (63% and 72%).
Surprisingly, B cell markers were more likely to exhibit
enhanced expression in the DLBCL component: CD19 and
CD79a were more strongly expressed in the DLBCL
component compared to the LP cells in 66% and 33% of
the cases, respectively (Table 2, Figure 3). The LP cells
were negative or only weakly positive for BCL2 in 82%.
However, BCL2 and CD10 (Figure 2d) were upregulated in
the DLBCL component in 38 and 33% of cases, re-
spectively. JAK2, p-STAT6, CD30, CD15, and IgD were
expressed in only a few cases of both DLBCL and NLPHL.
There was no correlation between the JAK2- and p-STAT6-
positive cases. The four cases strongly expressing
CD15 (>80% of the tumor cells) in the DLBCL component
were CD30-negative. All cases were negative for EBER.
Independent series of conventional DLBCL
In order to compare DLBCL transformed from NLPHL
(“LP type” DLBCL) with conventional DLBCL and to
identify more cases that may be derived from NLPHL,
we evaluated an independent series of 41 DLBCL for
their morphology and immunophenotype. Because of
the high prevalence of males in the first series, we
decided to investigate all males diagnosed with DLBCL
at the Pathology Department of Tampere between 2003
and 2013. Clinical data are shown in Table 1. Because
we had observed typical positivity for BCL6, CD75,PHL and DLBCL
Enhanced
xpression in DLBCL
component
Identical expression in
DLBCL and NLPHL
component
Identical expression in
DLBCL and NLPHL in
simultaneous cases
0% 97% 96%
33% 67% 62%
66% 31% 32%
9% 79% 81%
6% 76% 85%
3% 70% 77%
38% 63% 69%
13% 75% 77%
23% 77% 82%
33% 67% 69%
5% 86% 89%
6% 88% 92%
12% 88% 85%
0% 97% 96%
component. Stainings were also assessed if there was an enhanced or
LPHL.
gative or weakly positive cases is given.
Figure 2 Typical and special features of “LP type” DLBCL in composite lymphomas. a. Typical blast infiltrate with broad pale cytoplasm and
lobulated LP cell-like nuclei (HE, 400×). b. Blast infiltrate strongly expressing EMA as observed in 73% of “LP type” DLBCL (EMA immunostaining,
200×). c. Expression of CD15 in the cytoplasm and Golgi field in 4 of 33 “LP type” DLBCL (CD15 immunostaining, 200×). d. Expression of CD10 in
the cytoplasm and Golgi in 36% of “LP type” DLBCL (CD10 immunostaining, 400×). e. IgD expression in blasts observed in 4 of 33 “LP type” DLBCL
(IgD immunostaining, 200×). f. JAK2 expression found in 43% of “LP type” DLBCL (JAK2 immunostaining, 100×).
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negativity or weak positivity for BCL2 in “LP type”
DLBCL, all cases of the second series were stained for
theses antigens and were additionally evaluated for the
presence of FDCs.
All cases were positive for CD20, and the majority
of cases were positive for BCL6, CD75, and MUM1
(83%, 85%, and 83%, respectively, Table 3). FDCs were
rarely observed in both “LP type” and conventional
DLBCL (Table 3). However, EMA (27%) and J-chain (22%)
were significantly less frequently positive (p < 0.05, 2-TailFisher´s Exact Test) in conventional DLBCL compared to
“LP type” DLBCL. Only three cases expressed both EMA
and J-chain (see below). Likewise, a negative or weakly
positive BCL2 staining was only observed in 32% of cases
of conventional DLBCL in the second series and was
significantly less frequently observed than in “LP type”
DLBCL (p < 0.05, 2-Tail Fisher´s Exact Test). Therefore
we selected all cases with a nodular, sheet-like growth
pattern or a histiocyte rich microenvironment and expres-
sion of BCL6, CD75, and J-chain and (or) EMA. Five cases
meeting these criteria, including the three EMA-J-chain
Figure 3 B cell phenotype in composite lymphomas of NLPHL and “LP type” DLBCL. a. Moderate CD20 expression in LP cells of NLPHL
(arrows: CD20, 200×). b. More enhanced CD20 expression in “LP type” DLBCL (same lymph node and same section, CD20, 200×). c. Weak CD79a
expression in LP cells of NLPHL (arrows: CD79a, 200×). d. More enhanced CD79a expression in “LP type” DLBCL (same lymph node, CD79a, 200×). e. Weak
CD19 expression in LP cells of NLPHL (arrows: CD19, 200×). f. More enhanced CD19 expression in “LP type” DLBCL (same lymph node, CD19, 200×).
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CD15, EBER, IgD, and CD19. One of these sheet-like
growing DLBCL, which was positive for BCL6, CD75,
J-chain, and EMA and involved the parotid gland of a
36 year-old male, could be excluded as a transformed
marginal zone lymphoma: after closer work-up of this case,
a low-grade lymphoma component with a typical follicular
colonization pattern was discovered in an additional
tissue block. Finally, four “LP type” DLBCL were identified
among the 41 DLBCL cases (10%, Figure 4). All four cases
were positive for BCL6, CD75, and EMA. Three cases
were additionally positive for J-chain and weakly positive
or negative for BCL2. One case was positive for IgD, onefor CD10, and one for CD30. All four cases were negative
for EBER and CD15.
Clinical features of four DLBCL cases with putative
derivation from NLPHL
The median age of these patients was 31.5 years. The
localization of the biopsies were cervical (in two cases),
axillary and mesenteric. One patient was diagnosed in
stage II, one in stage III, and two in stage IV. Three of four
patients presented splenic involvement, and two of these
additionally presented liver involvement. Two patients
achieved complete remission after R-CHOP/R-CHOEP,
and one patient achieved remission after R-CHOP and
Table 3 Immunophenotype of “LP type” DLBCL (transformed from NLPHL) compared to conventional DLBCL
Staining pattern typically observed in DLBCL transformed from NLPHL “LP type” DLBCL (n = 33) Conventional DLBCL (n = 41)
Bcl-6 strongly positive 33 (100%) 34 (83%)
CD10 weakly or strongly positive 12 (36%) 15 (37%)
CD75 weakly or strongly positive 31 (94%) 35 (85%)
EMA weakly or strongly positive 24 (73%)* 11 (27%)*
MUM1 weakly or strongly positive 21 (63%) 34 (83%)
J-chain weakly or strongly positive 24 (73%)* 9 (22%)*
Bcl2 weakly positive or negative 20 (63%)* 13 (32%)*
CD21-positive follicular dendritic cells 1/28 (4%) 5/28 (18%)
CD23-positive follicular dendritic cells 0/28 (0%) 5/28 (18%)
*Staining patterns which were significantly more frequently observed in “LP type” DLBCL compared to conventional DLBCL are printed in bold (p < 0.05, 2-Tail
Fisher´s Exact Test).
Figure 4 “LP type” DLBCL, presumably transformed from NLPHL. Cervical lymph node biopsy of one of the patients presenting with “LP
type” DLBCL. a. HE, 40×. The lymph node architecture is effaced with open sinuses. b. HE, 400×. Higher magnification reveals a blast infiltrate with
a broad, pale cytoplasm and large numbers of histiocytes. c. Blasts stain partly positive for CD75 (400×). d. A subset of blasts is positive for J-chain
(400×). e. The infiltrate weakly expresses EMA (200×). f. IgD is strongly expressed in the blast population (400×).
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received DHAP but died few months after diagnosis.
Discussion
In the present study we investigated 33 patients with
NLPHL and transformation into DLBCL. Although 26 of
33 patients in the present study showed a simultaneous
presentation of NLPHL and DLBCL, the clinical data
match well with previous studies of secondary transforma-
tions of NLPHL into DLBCL [16,17]. Histopathologic
variant patterns (“Non-A/B”) as described by Fan et al. [4]
were seen in the NLPHL component in 70% of composite
cases investigated in the present study. Histopathologic
variants have been associated with advanced stage
and an increased risk of relapse [4,5,22] and the high
frequency in the present study likely points to an
increased risk of transformation into DLBCL in these
patients.
In the present study, we observed in most composite
NLPHL-DLBCL cases, a particular pattern of infiltration
with a sharply demarcated sheet-like blast expansion or
with a relatively high number of histiocytes admixed
with the DLBCL component. The morphology of the
nuclei was variable, as previously observed [14]. The most
common immunophenotype, differing from conventional
DLBCL, was coexpression of EMA and J-chain. However,
this immunophenotype was not specific. EMA expression
in DLBCL derived from NLPHL was also observed in one
previous study [14]. Another remarkable observation was
the upregulation of B cell markers as well as BCL2 in the
DLBCL component compared to the NLPHL component.
Possibly, the slight downregulation of B cell receptor
signaling observed in the LP cells of NLPHL [6,8] is
substituted by stimulation from rosetting follicular T
helper cells. Since T cell rosetting was never observed
in the DLBCL component, these tumor cells must
have acquired additional properties to ensure their
survival. One of these features may represent enhanced
tonic active B cell receptor signaling [23-25] or the
upregulation of BCL2 anti-apoptotic protein [26,27]. The
increased number of tumor cells in “LP type” DLBCL
compared to the NLPHL component may result from
enhanced anti-apoptotic properties resulting from BCL2
expression. In the present series, p-STAT6 and JAK2
were expressed in both components less frequently than
previously observed [9]. Possibly, SOCS1-mutated NLPHL
cases with active JAK-STAT-signaling are less likely to
transform into DLBCL and may, therefore, have a
better prognosis similar to DLBCL with truncating
SOCS1 mutations [28]. We also observed upregulation of
CD15 and CD10 in some cases of “LP type” DLBCL.
CD15 expression has been described in a subset of
NLPHL-DLBCL composite lymphomas [14], whereas
CD15 expression in NLPHL generally is a rare phenomenon[3,29,30]. Upregulation of these markers may be associated
with activation of the tumor cells as observed for CD30
expression [31-33].
Since we also identified four cases with a typical “LP
type” infiltration pattern and immunophenotype in a
series of conventional DLBCL, we hypothesize that a
series of conventional DLBCL cases will include cases
with transformation from NLPHL, particularly if diagnoses
are made on small core biopsies. Since some of the
composite cases showed a downregulation of J-chain and
EMA as well as an upregulation of CD10 and BCL2 in the
DLBCL component, these cases may be difficult to identify
applying current histopathologic methods if only the
DLBCL component is sampled. Furthermore, the immuno-
histochemical stainings, observed to be frequently positive
in the present study, were not specific, as was demonstrated
in the case of transformed marginal zone lymphoma, which
was positive for both EMA and J-chain.Conclusions
In the present study we observed a heterogeneous immu-
nophenotype of DLBCL derived from NLPHL, which may
reflect different mechanisms of transformation. This fact
makes these cases difficult to recognize, if the NLPHL
component is not sampled. Men with sharply demarcated
blast infiltrates with EMA- and/or J-chain expression and
abdominal, splenic, or axillary localization are more likely
to have “LP type” DLBCL. However, it is important to
state, that by applying current immunohistochemical
markers, there is no way to specifically recognize these
cases unless the coexisting NLPHL component can be
identified. Therefore, further characterization of the
particular clinical and molecular features of “LP type”
DLBCL among conventional DLBCL is warranted, and
may lead to identification of better diagnostic markers.Additional files
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